#Canada #Montreal #World Federation of Hemophilia #Hemophilia Treatment #WHO Essential Medicines

A Significant Milestone in Global Health

The recent updates to the World Health Organization's (WHO) Essential Medicines List (EML) represent a monumental step forward for individuals living with bleeding disorders, particularly hemophilia and von Willebrand Disease (VWD). Spearheaded by the World Federation of Hemophilia (WFH), this initiative aimed to align the EML with the latest international clinical guidelines and improve the accessibility of requisite medicines for patients across the globe.

Enhanced Access to Life-Saving Treatments

The new revisions include the addition of critical medications that are integral to the treatment and management of hemophilia and VWD. The inclusion of bi-specific monoclonal antibody emicizumab and various recombinant clotting factor concentrates marks a significant advancement in therapeutic options available to healthcare providers and patients. The WHO EML plays a crucial role in shaping national policies about which medications are deemed essential for public health. Thus, by ensuring that these updated medications are included, the WFH aims to provide hope for a better quality of life for the estimated thousands of individuals affected by these conditions worldwide.

In light of the updated guidelines, decision-makers will have access to the most current evidence-based practices when it comes to treating bleeding disorders. As a result, they can make informed decisions that directly affect the lives of people living with these challenging health issues.

Moving Towards a Brighter Future

Cesar Garrido, President of WFH, emphasized the historical significance of these updates during a recent address, stating: "The updates to the WHO EML mean that thousands of PWBDs now have greater hope for a better future." Such advancements underscore the WFH's dedication to making their vision of 'Treatment for All' a reality. This is especially crucial in the context of universal health coverage, where every life affected by hemophilia deserves care and support.

The Process Behind the Updates

This remarkable achievement was not instantaneous; it hinged upon extensive global collaboration and advocacy. The WFH engaged in a two-year dialogue with WHO Headquarters, substantiating their requests for vital revisions to the EML. Insights were shared with WHO through presentations at crucial meetings and publication of research papers, emphasizing the risks posed by the outdated recommendations in treating hemophilia.

Letters of support for these critical changes were solidified not only by national member organizations of the WFH but also by over 120 expert clinicians from various regions. This widespread backing exemplifies how the global community can unite towards a common cause, enhancing the quality of life for those living with bleeding disorders.

Focus on Safety and Efficacy

The revisions have also led to the removal of certain medications previously included in the EML that posed risks, such as cryoprecipitate, due to its association with bloodborne infections. Such moves to prioritize virally safe treatments ensure that individuals with hemophilia and VWD are no longer subjected to a risk-laden therapeutic landscape. Along the same lines, the revised EML and EMLc (Essential Medicines List for Children) now comprehensively reflect the safest and most effective therapies available, ensuring equitable access for all patients globally.

Conclusion: United for a Common Cause

As the global community looks towards renewed efforts in treating bleeding disorders, the recent updates to the WHO Essential Medicines List reiterate the necessity for collaboration, advocacy, and ongoing dialogue in order to achieve the ultimate goal: universal access to safe and effective treatments for hemophilia and other bleeding disorders. The WFH continues to stand at the forefront, dedicated to empowering individuals and families affected by these conditions and transforming hopes for a better future into actionable realities.

For more information about the WFH and their initiatives, visit their official website at www.wfh.org.